Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$27.79
+6.6%
$25.96
$14.80
$40.47
$2.12B0.861.00 million shs622,288 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.87
+2.4%
$13.71
$8.02
$15.78
$7.39B1.675.04 million shs1.93 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.59
+0.4%
$11.13
$8.73
$13.06
$7.86B1.155.73 million shs2.11 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$104.78
+0.0%
$85.95
$18.51
$104.99
$8.92B0.241.71 million shs3.45 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+4.53%-3.55%+2.44%+26.36%-30.73%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.69%-1.97%+3.61%+71.83%+9.50%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+1.58%+2.85%+4.15%+13.69%-0.60%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-0.03%-0.03%+12.99%+77.77%+370.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.5105 of 5 stars
4.51.00.00.02.70.80.0
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.5544 of 5 stars
1.31.00.00.32.01.71.3
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.6493 of 5 stars
3.63.00.00.02.32.50.0
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.3057 of 5 stars
2.15.00.00.02.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
3.08
Buy$55.3098.97% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.63
Moderate Buy$16.007.64% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.25
Buy$16.5042.43% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.15
Hold$109.004.03% Upside

Current Analyst Ratings Breakdown

Latest CGON, VRNA, ROIV, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$18.00
7/16/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$68.00 ➝ $53.00
7/14/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$90.00 ➝ $107.00
7/10/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$40.00
7/10/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$19.00
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$138.00 ➝ $107.00
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/9/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$662K3,200.18N/AN/A$9.63 per share2.89
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.66$2.29 per share6.48$12.33 per share1.21
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M271.08N/AN/A$7.45 per share1.56
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$42.28M210.96N/AN/A$2.56 per share40.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$88.04M-$1.51N/AN/AN/A-15,945.17%-16.71%-16.24%8/14/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7420.1116.702.868.43%7.54%3.57%8/7/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$2.00N/A3,492.50N/AN/A-69.65%-28.00%8/6/2025 (Estimated)

Latest CGON, VRNA, ROIV, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.49N/AN/AN/AN/AN/A
8/14/2025Q1 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.23N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989N/AN/AN/A$1.19 billionN/A
8/6/2025Q2 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$0.39N/AN/AN/A$68.24 millionN/A
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/13/2025Q1 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
4/29/2025Q1 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
30.97
30.97
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.07
8.86
8.73
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.23 million70.58 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3085.13 million81.05 millionOptionable

Recent News About These Companies

Pharmaceutical Stocks To Research - July 14th

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$27.79 +1.71 (+6.57%)
As of 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.86 +0.36 (+2.45%)
As of 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.58 +0.05 (+0.39%)
As of 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$104.78 +0.04 (+0.03%)
As of 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.